<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00215462</url>
  </required_header>
  <id_info>
    <org_study_id>00-012</org_study_id>
    <nct_id>NCT00215462</nct_id>
  </id_info>
  <brief_title>Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma</brief_title>
  <official_title>A Phase II Study of Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect anti-tumor activity of vinorelbine when given to&#xD;
      patients with esophageal or gastric tumors. We will also collect information on the&#xD;
      toxicities of vinorelbine in these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Patients will receive vinorelbine intravenously once per week for eight weeks. These&#xD;
           treatments will be repeated after the initial eight weeks as long as the patient&#xD;
           continues to receive benefit from the treatment. If the patient experiences significant&#xD;
           toxicities, the dose may be reduced or the chemotherapy may be discontinued.&#xD;
&#xD;
        -  Before beginning treatment and during therapy, routine laboratory tests, scans and&#xD;
           x-rays will be done to check the body's response to treatment. A physical exam will be&#xD;
           done at the start of the study and before each course of treatment. Scans will be done&#xD;
           after eight weeks of therapy.&#xD;
&#xD;
        -  Patients will remain on this study as long as their disease does not become worse or&#xD;
           they do not experience severe side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the anti-tumor activity of vinorelbine when administered to patients with locally advanced or metastatic esophageal or gastric adenocarcinoma.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the toxicities of vinorelbine in this patient population.</measure>
  </secondary_outcome>
  <enrollment>32</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Stomach Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Locally unresectable or metastatic esophageal adenocarcinoma. Locally unresectable or&#xD;
             metastatic gastric adenocarcinoma. Only patients with measurable tumors are eligible.&#xD;
&#xD;
          -  No more than one prior chemotherapy regimen&#xD;
&#xD;
          -  ECOG performance status of 0-1&#xD;
&#xD;
          -  Life expectancy of &gt; 12 weeks&#xD;
&#xD;
          -  Greater than or equal to 1,200 calorie/day intake&#xD;
&#xD;
          -  ANC &gt; 1,500/mm3&#xD;
&#xD;
          -  AST &lt; 3 x ULN&#xD;
&#xD;
          -  Total bilirubin &lt; 2.0 ng/dl&#xD;
&#xD;
          -  Platelets &gt; 100,000/mm3&#xD;
&#xD;
          -  Serum creatinine &lt; 2.0 mg/dl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior therapy with vinca alkaloids&#xD;
&#xD;
          -  Chemotherapy within the past three weeks&#xD;
&#xD;
          -  Clinically apparent central nervous system metastases or carcinomatous meningitis&#xD;
&#xD;
          -  Peripheral neuropathy &gt; 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Kulke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>April 27, 2009</last_update_submitted>
  <last_update_submitted_qc>April 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2009</last_update_posted>
  <responsible_party>
    <name_title>Matthew Kulke, MD</name_title>
    <organization>Dana-Farber Cancer Institute</organization>
  </responsible_party>
  <keyword>gastric adenocarcinoma</keyword>
  <keyword>esophageal adenocarcinoma</keyword>
  <keyword>vinorelbine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

